Orchid Pharma Limited (BOM:524372)
India · Delayed Price · Currency is INR 664.50
-11.05 (-1.64%)
At close: Feb 13, 2026
Orchid Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 8,112 | 9,219 | 8,194 | 6,659 | 5,596 | 4,501 |
Revenue Growth (YoY) | -10.02% | 12.52% | 23.05% | 19.00% | 24.33% | -6.97% |
Cost of Revenue | 5,355 | 5,672 | 5,032 | 4,013 | 3,271 | 2,413 |
Gross Profit | 2,757 | 3,548 | 3,162 | 2,646 | 2,325 | 2,088 |
Selling, General & Admin | 947.09 | 882.37 | 729.83 | 663.66 | 648.58 | 686.14 |
Other Operating Expenses | 1,384 | 1,490 | 1,323 | 1,145 | 1,145 | 817.22 |
Operating Expenses | 2,686 | 2,718 | 2,386 | 2,357 | 2,664 | 2,593 |
Operating Income | 71.1 | 829.5 | 776.25 | 289.93 | -338.9 | -504.94 |
Interest Expense | -140.83 | -145.4 | -163.55 | -322.26 | -320.12 | -513.36 |
Interest & Investment Income | 172.77 | 172.77 | 163.48 | 6.18 | 4.19 | 7.33 |
Earnings From Equity Investments | 15.05 | 38.99 | -28.98 | -21.54 | -35.23 | - |
Currency Exchange Gain (Loss) | 64.29 | 64.29 | 67.35 | 52.01 | 75.82 | 34.91 |
Other Non Operating Income (Expenses) | 80.22 | 37.68 | 77.8 | 126.6 | 4.9 | 4.81 |
EBT Excluding Unusual Items | 262.61 | 997.83 | 892.36 | 130.93 | -609.34 | -971.26 |
Gain (Loss) on Sale of Investments | - | - | - | 0.15 | 5.12 | 19.42 |
Gain (Loss) on Sale of Assets | -3.2 | -3.2 | -1.88 | 7.75 | 0 | -0.65 |
Other Unusual Items | -71.13 | - | - | 392.1 | - | - |
Pretax Income | 188.29 | 994.63 | 890.47 | 530.93 | -604.21 | -952.49 |
Income Tax Expense | -2.33 | -1.94 | -31.19 | - | - | - |
Earnings From Continuing Operations | 190.61 | 996.57 | 921.67 | 530.93 | -604.21 | -952.49 |
Earnings From Discontinued Operations | - | - | - | -67.75 | 584.7 | -212.81 |
Net Income to Company | 190.61 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 |
Net Income | 190.61 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 |
Net Income to Common | 190.61 | 996.57 | 921.67 | 463.18 | -19.51 | -1,165 |
Net Income Growth | -82.81% | 8.13% | 98.98% | - | - | - |
Shares Outstanding (Basic) | 51 | 51 | 48 | 41 | 41 | 41 |
Shares Outstanding (Diluted) | 51 | 51 | 48 | 41 | 41 | 41 |
Shares Change (YoY) | -0.30% | 4.87% | 18.49% | - | - | 9914.82% |
EPS (Basic) | 3.77 | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
EPS (Diluted) | 3.77 | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
EPS Growth | -82.76% | 3.11% | 67.93% | - | - | - |
Free Cash Flow | - | -1,309 | 611.77 | -665.75 | 780.71 | 229.82 |
Free Cash Flow Per Share | - | -25.81 | 12.65 | -16.31 | 19.13 | 5.63 |
Gross Margin | 33.99% | 38.48% | 38.59% | 39.74% | 41.55% | 46.38% |
Operating Margin | 0.88% | 9.00% | 9.47% | 4.35% | -6.06% | -11.22% |
Profit Margin | 2.35% | 10.81% | 11.25% | 6.96% | -0.35% | -25.89% |
Free Cash Flow Margin | - | -14.20% | 7.47% | -10.00% | 13.95% | 5.11% |
EBITDA | 428.55 | 1,170 | 1,094 | 837.72 | 531.03 | 583.9 |
EBITDA Margin | 5.28% | 12.69% | 13.35% | 12.58% | 9.49% | 12.97% |
D&A For EBITDA | 357.45 | 340.42 | 317.72 | 547.79 | 869.93 | 1,089 |
EBIT | 71.1 | 829.5 | 776.25 | 289.93 | -338.9 | -504.94 |
EBIT Margin | 0.88% | 9.00% | 9.47% | 4.35% | -6.06% | -11.22% |
Revenue as Reported | 8,429 | 9,494 | 8,502 | 6,853 | 5,686 | 4,653 |
Updated Dec 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.